Recent Progress in Immunotherapy of Breast Cancer Targeting the Human Epidermal Growth Factor Receptor 2 (Her2) Publisher Pubmed



Seyedmirzaei H^{1, 2} ; Keshavarzfathi M^{1, 2, 3} ; Razi S^{1, 4} ; Gity M^{3, 5} ; Rezaei N^{1, 6, 7} Show Affiliations
Source: Journal of Oncology Pharmacy Practice Published:2021

Abstract

Objective: Breast cancer is responsible for most of the cancer-induced deaths in women around the world. The current review will discuss different approaches of targeting HER2, an epidermal growth factor overexpressed in 30% of breast cancer cases. Data sources: We conducted a search on Pubmed and Scopus databases to find studies relevant to HER2+ breast cancers and targeting HER2 as means of immunotherapy. Out of 1043 articles, 105 studies were included in this review. Data summary: As well as the introduction of HER2 and breast cancer subtypes, we discussed various aspects of HER2-targeting immunotherapy including monoclonal antibodies, Antibody-drug conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cells and vaccines. Conclusions: Despite several ways of controlling breast cancer, the need to investigate new drugs and approaches seems to be much significant as this cancer still has a heavy burden on people’s health and survival. © The Author(s) 2021.